文献速递银屑病与炎症性皮肤病

阿达木单抗单药与联合甲氨蝶呤治疗银屑病比较

Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis.
PubMed 文献 · JAMA Dermatol · 2025-01-01

该目标试验模拟队列研究利用英国皮肤科医师协会生物制剂与免疫调节剂注册库2007至2021年数据,比较阿达木单抗单药与联合甲氨蝶呤治疗斑块状银屑病的效果。结果显示两组在1年药物生存率、PASI75应答及严重不良事件方面无差异,但联合组抗药抗体水平较低。

要点

  • 阿达木单抗联合甲氨蝶呤与单药在1年药物生存率上无显著差异。
  • 两组1年和3年PASI75应答率及严重不良事件均无显著差异。
  • 联合甲氨蝶呤组抗药抗体水平显著低于单药组。

核心结论

  • 在斑块状银屑病患者中,阿达木单抗单药与联合甲氨蝶呤在有效性和持久性方面无差异证据。

研究设计与样本

  • 目标试验模拟队列研究,模拟OPTIMAP试验关键设计,使用英国皮肤科医师协会生物制剂与免疫调节剂注册库2007至2021年数据。
  • 干预组231例接受阿达木单抗40mg每两周一次联合每周甲氨蝶呤(剂量由临床医生决定),对照组1553例接受阿达木单抗40mg每两周一次单药治疗。

主要发现

  • 1年药物生存率:对照组78.1%(95%CI 76.1%-80.2%),干预组79.1%(95%CI 71.8%-87.2%),差异1.0%(95%CI -7.0%至8.9%)。
  • 1年PASI75:对照组52.0%(95%CI 47.7%-56.3%),干预组49.4%(95%CI 31.5%-67.3%),差异-2.5%(95%CI -21.0%至15.9%)。
  • 3年PASI75:对照组32.4%(95%CI 28.0%-36.8%),干预组37.2%(95%CI 16.8%-57.6%),差异4.9%(95%CI -16.1%至25.7%)。
  • 干预组抗药抗体水平较低(风险差异-123.7 AU/mL,95%CI -200.5至-46.9)。

临床怎么用

  • 对于斑块状银屑病患者,阿达木单抗单药治疗即可,无需常规联合甲氨蝶呤以增强疗效或持久性。
  • 联合甲氨蝶呤可降低抗药抗体水平,但临床意义需进一步研究。

局限性

  • 观察性研究设计可能存在残余混杂。
  • 干预组样本量较小(231例),结果精确度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether concomitant methotrexate enhances the effectiveness and persistence of adalimumab for psoriasis. The recent OPTIMAP randomized clinical trial that tested adalimumab against adalimumab with methotrexate could not adequately answer this question due to underrecruitment. OBJECTIVE: To determine the effectiveness of using methotrexate with adalimumab in people with plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: This target trial emulation cohort study replicated key aspects of the OPTIMAP trial design using the British Association of Dermatologists Biologics and Immunomodulators Register between 2007 and 2021. EXPOSURES: Adalimumab, 40 mg, every other week monotherapy (comparator) vs adalimumab, 40 mg, every other week and methotrexate weekly, with the dosage as determined by the clinician (intervention). MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in the adalimumab survival function at 1 year. The secondary outcomes included differences in adalimumab survival function at 3 years; 75% reduction in Psoriasis Area and Severity Index (PASI75) at 1 year and 3 years; serious adverse events at 1 and 3 years; and adalimumab concentrations and antidrug antibodies at 1 year. Inverse probability treatment and censoring weighting were used for covariate and missing outcome adjustment. Flexible parametric survival models were fitted for survival outcomes and generalized linear models for other outcomes. RESULTS: There were 231 and 1553 participants (754 female individuals [42.3%]) in the intervention (median [IQR] age, 43.7 [35.1-53.1] years) and comparator (median [IQR] age, 43.6 [34.2-52.0] years) arms, respectively. Drug survival for the comparator arm at 1 year was 78.1% (95% CI, 76.1%-80.2%) and the intervention arm was 79.1% (95% CI, 71.8%-87.2%), with no evidence of difference (1.0%; 95% CI, -7.0% to 8.9%). PASI75 at 1 year and 3 years in the comparator arm was 52.0% (95% CI, 47.7%-56.3%) and 32.4% (95% CI, 28.0%-36.8%), respectively; in the intervention arm, PASI75 was 49.4% (95% CI, 31.5%-67.3%) and 37.2% (95% CI, 16.8%-57.6%), respectively. There was no evidence of differences at 1 year and 3 years (-2.5%; 95% CI, -21.0% to 15.9% and 4.9%; 95% CI, -16.1% to 25.7%, respectively). There was no evidence for a difference between the 2 arms for serious adverse events and adalimumab concentrations, while the intervention arm had a lower antidrug antibody level (risk difference, -123.7 AU/mL; 95% CI, -200.5 to -46.9). CONCLUSION AND RELEVANCE: The results of this cohort study suggest that there was no evidence of a difference in the effectiveness and persistence of adalimumab in people with psoriasis between monotherapy and adalimumab with concomitant methotrexate.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Yiu ZZN, Smith CH, Laws P, et al. Adalimumab Monotherapy vs Adalimumab With Methotrexate for Psoriasis. JAMA Dermatol. 2025. PMID: 40465280. doi:10.1001/jamadermatol.2025.1463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。